Reports
Reports
Sale
The global psoriatic arthritis treatment market value was USD 10.1 billion in 2022, driven by the prevalence of psoriatic arthritis across the globe. The market size is anticipated to grow at a CAGR of 9.8% during the forecast period of 2023-2031 to achieve a value of USD 23.5 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
It is estimated that psoriasis affects more than 125 million individuals around the globe, and psoriasis tends to create psoriatic arthritis in 30% of the population. The global industry for psoriatic arthritis treatment is influenced by an increasing acceptance of medical therapy by patients suffering from moderate to serious psoriatic arthritis.
Psoriatic arthritis is a chronic psoriasis-related degenerative disorder. Swollen fingers, toes, and tender joints, stiffness, lowered back pain, and pitted nails are prevalent symptoms of psoriatic arthritis. Psoriatic arthritis treatment market can be divided on the basis of segments like drug class, product type and administration route.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of its drug class, the market can be widely categorised as:
Based on its product type, the market can be bifurcated as prescription and OTC.
The different administration route available for psoriatic arthritis treatment are topical, oral and injectable.
The EMR report looks into the regional psoriatic arthritis treatment markets like the North America, Latin America, Europe, Middle East and Africa, and Asia Pacific.
The intensive research taking place to provide treatment to the patients suffering from psoriasis condition is driving the global psoriatic arthritis treatment industry. The other factors aiding in the growth of the industry are investments by major companies in clinical R&D, new product launches, increasing disease prevalence and proactive government initiatives. The factors such as high cost of treatment, stringent regulatory approval and adverse effect of drugs may hinder the growth of the market in coming future.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global psoriatic arthritis treatment industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s five forces.
REPORT FEATURES | DETAILS |
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Drug Type |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Psoriatic Arthritis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Psoriatic Arthritis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Psoriatic Arthritis Epidemiology (2016-2031)
5.3 Europe Psoriatic Arthritis Epidemiology (2016-2031)
5.4 Asia-Pacific Psoriatic Arthritis Epidemiology (2016-2031)
5.5 Latin America Psoriatic Arthritis Epidemiology (2016-2031)
5.6 Middle East & Africa Psoriatic Arthritis Epidemiology (2016-2031)
6 Global Psoriatic Arthritis Treatment Market Overview
6.1 Global Psoriatic Arthritis Treatment Market Historical Value (2016-2022)
6.2 Global Psoriatic Arthritis Treatment Market Forecast Value (2023-2031)
7 Global Psoriatic Arthritis Treatment Market Landscape
7.1 Psoriatic Arthritis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Psoriatic Arthritis Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Drug Type
7.2.3 Analysis by Route of Administration
8 Psoriatic Arthritis Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Psoriatic Arthritis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Psoriatic Arthritis Treatment Market Segmentation
11.1 Global Psoriatic Arthritis Treatment Market by Drug Class
11.1.1 Market Overview
11.1.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
11.1.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
11.1.4 Immunosuppressants
11.1.5 Biological Agents
11.1.6 Corticosteroids
11.1.7 Others
11.2 Global Psoriatic Arthritis Treatment Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Topical
11.3 Global Psoriatic Arthritis Treatment Market by Drug Type
11.3.1 Market Overview
11.3.2 Prescription
11.3.2.1 Branded
11.3.2.2 Generics
11.3.3 Over The Counter
11.4 Global Psoriatic Arthritis Treatment Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.5 Global Psoriatic Arthritis Treatment Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Psoriatic Arthritis Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Psoriatic Arthritis Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Psoriatic Arthritis Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Psoriatic Arthritis Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Psoriatic Arthritis Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 AbbVie Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Janssen Global Services, LLC (Johnson & Johnson)
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Biogen Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Eli Lilly and Company
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 UCB S.A.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bristol-Myers Squibb Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Others
24 Psoriatic Arthritis Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2022, the global market psoriatic arthritis treatment attained a value of USD 10.1 billion.
The market is anticipated to grow at a CAGR of 9.8% during the forecast period of 2023-2031 to reach a value of USD 23.5 billion by 2031.
The major drivers of the market include the increasing acceptance of medical therapy by patients suffering from moderate to serious psoriatic arthritis, new product launches, growing disease prevalence, and rising government initiatives.
The intensive research taking place to provide treatment to the patients suffering from psoriasis condition is the key industry trend propelling the growth of the market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading drug classes of psoriatic arthritis treatment in the industry are NSAIDs, DMARDs, and biologics, among others.
The significant product types in the market are prescription and OTC.
The major routes of administration of psoriatic arthritis treatment in the industry are topical, oral, and injectable.
The major players in the industry are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., UCB SA, and AstraZeneca plc, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.